NEWS
Tonix Pharmaceuticals Announces Two Oral Presentations and One Poster Presentation Involving TNX-1500 (Fc-modified humanized anti-CD40L mAb) at the American Transplant Congress 2024Tonix Pharmaceuticals announced its participation at the American Transplant Congress 2024, revealing promising data for their drug TNX-1500.
The company shared two oral presentations and one poster presentation. The key highlights include the potential of TNX-1500 as a monotherapy or in combination to prevent organ rejection in allograft and xenograft animal models, promising outcomes in nonhuman primate and gene-edited pig heart models, and the expansion of immune tolerance protocols.
Tonix also completed a Phase 1 study of TNX-1500, assessing its safety and pharmacokinetics, and plans to move to Phase 2 trials in kidney transplant recipients.
The company shared two oral presentations and one poster presentation. The key highlights include the potential of TNX-1500 as a monotherapy or in combination to prevent organ rejection in allograft and xenograft animal models, promising outcomes in nonhuman primate and gene-edited pig heart models, and the expansion of immune tolerance protocols.
Tonix also completed a Phase 1 study of TNX-1500, assessing its safety and pharmacokinetics, and plans to move to Phase 2 trials in kidney transplant recipients.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1085Followers
68Following
7487Visitors
Follow